Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Agnello, Melissa ^a   Wong Beringer, Annie ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; COEVOLUTION; EXOS GENE; EXOU GENE; GENE MUTATION; GENE STRUCTURE; GENOTYPE; GYRA GENE; GYRB GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARC GENE; PARE GENE; PSEUDOMONAS AERUGINOSA; QUINOLONE RESISTANCE DETERMINING REGION; TYPE III SECRETION SYSTEM;

ADP RIBOSE TRANSFERASES; BACTERIAL PROTEINS; BACTERIAL TOXINS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; PNEUMONIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; VIRULENCE;

PSEUDOMONAS AERUGINOSA;

EID: 84864647674     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042973     Document Type: Article

References (43)

1. Veesenmeyer JL, Hauser AR, Lisboa T, Rello J, (2009) Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit Care Med 37: 1777-1786.
2. Feltman H, Schulert G, Khan S, Jain M, Peterson L, et al. (2001) Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 147: 2659-2669.
3. El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H, (2012) Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med. 40: 1157-63.
4. Shaver CM, Hauser AR, (2004) Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect Immun 72: 6969-6977.
5. Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, et al. (2001) Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 183: 1767-1774.
6. Schulert GS, Feltman H, Rabin SD, Martin CG, Battle SE, et al. (2003) Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis 188: 1695-1706.
7. El Solh AA, Akinnusi ME, Wiener-Kronish JP, Lynch SV, Pineda LA, et al. (2008) Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 178: 513-519.
8. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, et al. (2003) Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289: 885-888.
9. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS, (2005) Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 118: 259-268.
10. Hsu DI, Okamoto MP, Murthy R, Wong-Beringer A, (2005) Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 55: 535-541.
11. Flamm RK, Weaver MK, Thornsberry C, Jones ME, Karlowsky JA, et al. (2004) Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother 48: 2431-2436.
12. Mouneimné H, Robert J, Jarlier V, Cambau E, (1999) Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 43: 62-66.
13. Nakano M, Deguchi T, Kawamura T, Yasuda M, Kimura M, et al. (1997) Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 41: 2289-2291.
14. Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ, (2003) Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents. Netherlands. pp. 409-413.
15. Hooper DC, (2001) Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 7: 337-341.
16. Jalal S, Ciofu O, Hoiby N, Gotoh N, Wretlind B, (2000) Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 44: 710-712.
17. Lee JK, Lee YS, Park YK, Kim BS, (2005) Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 25: 290-295.
18. Akasaka T, Onodera Y, Tanaka M, Sato K, (1999) Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV. Antimicrob Agents Chemother 43: 530-536.
19. Breidenstein EB, de la Fuente-Núñez C, Hancock RE, (2011) Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 19: 419-26.
20. Wong-Beringer A, Wiener-Kronish J, Lynch S, Flanagan J, (2008) Comparison of type III secretion system virulence among fluoroquinolone-susceptible and-resistant clinical isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 14: 330-336.
21. Garey KW, Vo QP, Larocco MT, Gentry LO, Tam VH, (2008) Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother 20: 714-720.
22. Zhu H, Conibear TC, Bandara R, Aliwarga Y, Stapleton F, et al. (2006) Type III secretion system-associated toxins, proteases, serotypes, and antibiotic resistance of Pseudomonas aeruginosa isolates associated with keratitis. Curr Eye Res 31: 297-306.
23. Lakkis C, Fleiszig SM, (2001) Resistance of Pseudomonas aeruginosa isolates to hydrogel contact lens disinfection correlates with cytotoxic activity. J Clin Microbiol 39: 1477-1486.
24. Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP, (1996) Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol 34: 1129-1135.
25. CLSI (2007) Performance standards for antimicrobial susceptibility testing: 17th Informational supplement. Wayne, PA. pp. M100-S117.
26. Ajayi T, Allmond LR, Sawa T, Wiener-Kronish JP, (2003) Single-nucleotide-polymorphism mapping of the Pseudomonas aeruginosa type III secretion toxins for development of a diagnostic multiplex PCR system. J Clin Microbiol 41: 3526-3531.
27. Jalal S, Wretlind B, (1998) Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb Drug Resist 4: 257-261.
28. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, et al. (2001) Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 45: 105-116.
29. Allewelt M, Coleman FT, Grout M, Priebe GP, Pier GB, (2000) Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infect Immun 68: 3998-4004.
30. Maatallah M, Cheriaa J, Backhrouf A, Iversen A, Grundmann H, et al. (2011) Population structure of Pseudomonas aeruginosa from five mediterranean countries: evidence for frequent recombination and epidemic occurrence of CC235. PLoS One 6: e25617.
31. Poole K, (2011) Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2: 65.
32. Akasaka T, Tanaka M, Yamaguchi A, Sato K, (2001) Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother 45: 2263-2268.
33. Ling JM, Chan EW, Lam AW, Cheng AF, (2003) Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong. Antimicrob Agents Chemother 47: 3567-3573.
34. Kudla G, Murray AW, Tollervey D, Plotkin JB, (2009) Coding-sequence determinants of gene expression in Escherichia coli. Science 324: 255-258.
35. Wang P, Zhang X, wang L, zhen Z, Tang M, et al. (2010) Subinhibitory concentrations of ciprofloxacin induce SOS response and mutations of antibiotic resistance in bacteria. pp. 511-517.
36. Cirz RT, O'Neill BM, Hammond JA, Head SR, Romesberg FE, (2006) Defining the Pseudomonas aeruginosa SOS response and its role in the global response to the antibiotic ciprofloxacin. J Bacteriol 188: 7101-7110.
37. Cirz RT, Chin JK, Andes DR, de Crécy-Lagard V, Craig WA, et al. (2005) Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol 3: e176.
38. Borowiec JA, Gralla JD, (1987) All three elements of the lac ps promoter mediate its transcriptional response to DNA supercoiling. J Mol Biol 195: 89-97.
39. Galán JE, Curtiss R, (1990) Expression of Salmonella typhimurium genes required for invasion is regulated by changes in DNA supercoiling. Infect Immun 58: 1879-1885.
40. Fournier B, Klier A, (2004) Protein A gene expression is regulated by DNA supercoiling which is modified by the ArlS-ArlR two-component system of Staphylococcus aureus. Microbiology 150: 3807-3819.
41. Ferrándiz MJ, Martín-Galiano AJ, Schvartzman JB, de la Campa AG, (2010) The genome of Streptococcus pneumoniae is organized in topology-reacting gene clusters. Nucleic Acids Res 38: 3570-3581.
42. Bagel S, Hullen V, Wiedemann B, Heisig P, (1999) Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob Agents Chemother 43: 868-875.
43. Steck TR, Franco RJ, Wang JY, Drlica K, (1993) Topoisomerase mutations affect the relative abundance of many Escherichia coli proteins. Mol Microbiol 10: 473-481.